We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-21.21%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$45.4M
AUM Growth
+$3.55M
Cap. Flow
+$12.9M
Cap. Flow %
28.32%
Top 10 Hldgs %
72.25%
Holding
50
New
3
Increased
9
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$13.3M
2
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$3.63M
3
BLUE
bluebird bio
BLUE
+$93.6K
4
EXEL icon
Exelixis
EXEL
+$92.2K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$58.1K

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$3.68M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$2.42M
3
LITS
Lite Strategy Inc
LITS
+$1.55M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$1.14M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$891K

Sector Composition

Rank Sector Weight
1 Healthcare 50.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBB icon
1
iShares Biotechnology ETF
IBB
$9.45B
$12.1M 26.53%
+125,000
New +$13.3M
IBB icon
2
CALL
iShares Biotechnology ETF
IBB
$9.45B
$8.2M 18.04%
+85,000
New +$9.02M
LABU icon
3
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$517M
$2.28M 5.01%
+3,465
New +$3.63M
PRQR icon
4
ProQR Therapeutics
PRQR
$244M
$2.19M 4.81%
138,461
– –
MTD icon
5
Mettler-Toledo International
MTD
$28.1B
$1.83M 4.03%
3,235
– –
ILMN icon
6
Illumina
ILMN
$29.5B
$1.47M 3.24%
5,045
-66
-1% -$20.4K
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$123B
$1.44M 3.16%
8,664
-63
-0.7% -$10.9K
IONS icon
8
Ionis Pharmaceuticals
IONS
$8.93B
$1.21M 2.65%
22,307
-986
-4% -$50.3K
QGEN icon
9
Qiagen
QGEN
$8.62B
$1.08M 2.39%
29,671
-148
-0.5% -$5.5K
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$1.08M 2.39%
19,127
-161
-0.8% -$10.1K
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$38.3B
$1.04M 2.29%
14,255
+756
+6% +$58.1K
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$1.02M 2.25%
10,487
-2,360
-18% -$279K
REGN icon
13
Regeneron Pharmaceuticals
REGN
$72.9B
$940K 2.07%
2,516
-15
-0.6% -$5.49K
LOXO
14
DELISTED
Loxo Oncology, Inc
LOXO
$870K 1.91%
6,210
– –
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.9B
$826K 1.82%
9,698
-156
-2% -$14.8K
INCY icon
16
Incyte
INCY
$25.8B
$776K 1.71%
12,205
-140
-1% -$9.09K
CELG
17
DELISTED
Celgene Corp
CELG
$640K 1.41%
9,983
+236
+2% +$17.4K
PCRX icon
18
Pacira BioSciences
PCRX
$1.04B
$484K 1.07%
11,250
– –
NKTR icon
19
Nektar Therapeutics
NKTR
$2.39B
$435K 0.96%
882
+95
+12% +$57.3K
EXEL icon
20
Exelixis
EXEL
$13.9B
$426K 0.94%
21,646
+5,171
+31% +$92.2K
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$356K 0.78%
3,534
-464
-12% -$48.1K
AMGN icon
22
Amgen
AMGN
$209B
$328K 0.72%
1,685
-156
-8% -$30.4K
BIIB icon
23
Biogen
BIIB
$30.9B
$320K 0.7%
1,062
+30
+3% +$9.57K
GRFS
24
Grifois
GRFS
$5.55B
$315K 0.69%
17,176
+731
+4% +$14.5K
KYNB
25
Kyntra Bio
KYNB
$27.4M
$310K 0.68%
268
-418
-61% -$470K
1
2

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q4 2018 Portfolio in Review

As of Q4 2018, Opus Point Partners Management held 50 positions worth $45.4M, up 8.5% from $41.9M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Opus Point Partners Management deployed $12.9M of net new capital in Q4 2018, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was iShares Biotechnology ETF: 125,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Alkermes, an estimated $650K trimmed.

  • Opus Point Partners Management's largest Q4 2018 buy was iShares Biotechnology ETF: 125,000 shares worth $12.1M.
  • Opus Point Partners Management added most to bluebird bio in Q4 2018, an estimated $93.6K increase.
  • Opus Point Partners Management's biggest Q4 2018 reduction was Alkermes, cutting an estimated $650K.
  • Opus Point Partners Management fully exited TESARO, Inc. in Q4 2018, selling an estimated $3.68M.
  • Opus Point Partners Management's ten largest holdings make up 72% of its $45.4M portfolio in Q4 2018.
  • Opus Point Partners Management opened 3 new positions and closed 10 in Q4 2018.
  • Opus Point Partners Management's portfolio value rose 8.5% quarter-over-quarter to $45.4M.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.